BioSpace News Archive

Presidio Bay Ventures partnered with Kinship Capital to acquire a piece of property in the Northern California city to redevelop into a space for the life sciences industry.

rBIO launched last week with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.

The U.S. Department of Defense awarded Moderna a contract worth $1,966,598,000 for an additional 100 million doses of its COVID-19 vaccine.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Collagen Matrix, Inc., a global leader in regenerative, collagen-based, xenograft-derived medical devices, and portfolio company of Linden Capital Partners (“Linden”), announced today the acquisition of Sunstar’s Degradable Solutions division (the “Co

Initiation of Phase 1/2 clinical study of novel peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein (FAP) expected 1H 2021 Will be the first peptide-targeted radionuclide therapy targeting FAP to enter clinical development

Moderna to Present at the Goldman Sachs 13 th Annual Healthcare CEOs Unscripted Conference: A View from the Top

OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, today announced the first surgery in the United Kingdom utilizing the new Pediatric Nailing Platform | FEMUR (“PNP|FEMUR”).

– Applied DNA’s safeCircle™ Program Integrates with CLEARED4 Digital Platform for Online Health Safety Management and Reporting, Option Geared for Scaling of High-Volume Testing Clients –

- 100% rate of BMT and engraftment in patients receiving therapeutic dose of Iomab-B and lower rates of sepsis and sepsis related Grade ≥3 adverse events compared to patients receiving salvage therapies at 75% enrollment recently highlighted in oral presentations at ASH 2020 Annual Meeting - Independent Data Monitoring Committee recommends SIERRA continue as planned to full enrollment of 150 patients; trial is currently over 75% enrolled